Companion Diagnostics (CDx) – your guide to developments, opportunities and revenues
See what the future holds for companion diagnostics. Visiongain’s brand new report gives you revenue predictions for the CDx market and its submarkets from 2015, helping you stay ahead.
Our 197-page report provides 114 tables, charts, and graphs. Discover the growing trends of this industry. In particular, our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, drivers and restraints, and revenue predictions.
Besides revenue forecast to 2025, this report provides you with market shares, business outlooks, qualitative analyses (including SWOT and Porter’s Fiver Forces Analysis), company profiles and commercial partnerships. Also, read the full transcript of two exclusive expert opinion interviews to inform you about prospects for investments and sales:
– ResearchDx, Dr Philip D. Cotter, Principal and Co-Founder of ResearchDx, and Laboratory Director of Pacific Diagnostics Clinical Laboratory, a subsidiary of ResearchDx
– Northern Institute for Cancer Research, Professor Herbie Newell, Professor of Cancer Therapeutics
Discover sales predictions for the overall IVD and CDx market
See how the CDx market is forecasted to perform compared to the rest of the IVD market up to 2025.
This will give you insight into the market share of the CDx market and how its market share in the IVD market is set to change over the forecast period.
See revenue forecasts for CDx submarkets from 2015 to 2025
Along with prediction of overall world market value to 2025, our report shows you revenue forecasting for the two submarkets at world level:
• Theranostics
• Other Companion Diagnostics
The analysis helps you identify potential with individual revenue forecasts and find ways for your business to develop.
Discover prospects for the leading nations and regions to 2025
The regional market reach for CDx products is expanding as regulatory bodies worldwide are mandating the approval of diagnostics simultaneously with therapies.
You will discover individual revenue forecasts to 2025 for 13 leading national markets and the rest of the world (RoW):
• US
• Japan
• Germany
• France
• UK
• Italy
• Spain
• China
• Brazil
• Russia
• India
• South Korea
• Mexico
• Rest of the World
The uptake of novel companion diagnostic platforms in the emerging economies will be a major driver of growth in this market.
Leading companion diagnostics companies and potential for market growth
Our new study predicts the world market for CDx will reach $3.32bn in 2015. The trend of pharmaceutical companies establishing partnerships and collaborations with companion diagnostic companies, in earlier drug development stages, continues to increase.
Our research profiles leading companies, assessing their financial performance and products. You will see which technologies and organisations hold the greatest potential. See the profiles of 9 leading companies:
• Roche Diagnostics (including Ventana Medical Systems)
• Qiagen
• Abbott Molecular
• Agilent (Dako)
• Myriad Genetics
• bioMérieux
• Siemens Healthcare
• Thermo Fisher Scientific
• Lab 21
In general, a company profile gives you the following information:
• Historical and recent revenue figures- including the individual diagnostics business sector
• Discussion of a company’s pipeline
• Assessment of recent developments – mergers and acquisitions (M&A), new products, collaborations, including alliances, companion diagnostics partnerships and joint ventures.
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What does the development pipeline look like in the CDx market?
Our report examines the current biomarkers and CDx test products on the market and also explores the future prospects of the CDx market:
• The current CDx diagnostic and pharmaceutical partnerships including the pipeline disease area
• The market potential of companion diagnostics across leading disease indications
• The competitive landscape of the CDx market.
What is currently restraining further growth in the CDx market?
Our report discusses issues and events affecting the industry and market from 2015, including these:
• The evolving regulatory framework around CDx and LDTs
• The vested interests of different stakeholders
• The reimbursement of CDx tests
• The opportunities of next-generation sequencing technologies
How The Companion Diagnostics (CDx) Market Forecast 2015-2025 report helps you:
In summary, our new 197-page report gives you the following knowledge:
• Revenue forecasts to 2025 for the world CDx market and 2 submarkets – Discover the industry’s prospects, finding promising places for investment and revenues.
• Revenue forecasts to 2025 for the leading 13 national markets – US, Japan, Germany, France, UK, Italy, Spain, Brazil, Russia, China, India, South Korea, Mexico and the Rest of the World
• Assessment of 9 leading companies – hear about CDx products, pipeline developments, financial results and strategies
• Review of R&D pipelines – investigate developmental trends and progress
• Analysis of what stimulates and restrains that industry and market – assess challenges and strengths, helping you compete and get advantages.
• View opinions from our survey, seeing interviews with leading CDx experts.
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our study you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the CDx market and leading diagnostic companies. You find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1. Executive Summary
1.1 The Companion Diagnostics Market Overview
1.2 Companion Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Companion Diagnostics
2.1 The Foundation of Personalised Medicine
2.2 Personalised Medicine: Changing the Patient Treatment Paradigm
2.3 In Vitro Diagnostic (IVD) Tests
2.3.1 Companion Diagnostics: A Type of IVD
2.3.2 Differences between Companion Diagnostics and Theranostics
2.3.4 Biomarkers to Companion Diagnostics
2.3.5 Genomic Biomarkers
2.3.6 Genomic Oncology Biomarkers
2.4 Regulations in the Companion Diagnostics Market
2.4.1 FDA's Final Guidance on Companion Diagnostics
2.4.2 LDTs: A Changing Landscape
2.5 Encouraging the Contemporaneous Development of Companion Diagnostics
3. The World Companion Diagnostics Market, 2015-2025
3.1 Scope and Limitations
3.2 The Global Companion Diagnostics Market, 2014
3.3 The Global Companion Diagnostics Market Sales Forecast, 2015-2025
3.4 Companion Diagnostics: Outpacing the Rest of the IVD Market
3.5 Companion Diagnostics: Increasing Market Share of the IVD Market
3.6 The Companion Diagnostics Market by Submarket, 2014
3.7 Theranostics: Will Outpace the Rest of the CDx Market
3.8 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2015-2025
4. Leading National Markets for Companion Diagnostics, 2015-2025
4.1 The Leading National Markets for Companion Diagnostics: Led by 3 Dominant Markets in 2014
4.2 The Leading National Markets for Companion Diagnostics Sales Forecast, 2015-2025
4.2.1 Changing Market Shares of Leading National Markets, 2015-2025
4.3 The US Companion Diagnostics Market Sales Forecast, 2015-2025
4.3.1 The U.S Will Continue to Dominate the Market
4.3.2 Leading Companion Diagnostics U.S Companies
4.4 The EU5 Companion Diagnostics Sales Market, 2014
4.4.1 The EU5 Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.2 Changing Market Shares of the EU5 Companion Diagnostics Market
4.4.3 The German Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.4 The French Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.5 The Italian Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.6 The Spanish Companion Diagnostics Market Sales Forecast, 2015-2025
4.4.7 The UK Companion Diagnostics Market Sales Forecast, 2015-2025
4.5 The Japanese Companion Diagnostics Market Sales Forecast, 2015-2025
4.5.1 Japan’s Slow Medical Technology Regulatory Process
4.6 The Chinese Companion Diagnostics Market Sales Forecast, 2015-2025
4.6.1 Cancer Rates will Drive Adoption of Companion Diagnostic tests
4.6.2 Ventana: A Major Player Moving into China’s Companion Diagnostics Space
4.7 The Indian Companion Diagnostics Market Sales Forecast, 2015-2025
4.8 The Brazilian Companion Diagnostics Market Sales Forecast, 2015-2025
4.9 The Russian Companion Diagnostics Market Sales Forecast, 2015-2025
4.10 The South Korean Companion Diagnostics Market Sales Forecast, 2015-2025
4.11 The Mexican Companion Diagnostics Market Sales Forecast, 2015-2025
4.12 The Rest of the World Companion Diagnostics Market Sales Forecast, 2015-2025
5. The Companion Diagnostics Market: Marketed Products and Pipeline Partnerships Market
5.1 Biomarkers: At the Forefront of Companion Diagnostics Development
5.2 U.S FDA Approved Companion Diagnostic Tests, 2015
5.3 Oncology Continues to Dominate the R&D Pipeline of Companion Diagnostics
5.4 Expensive Cancer Therapies Encourages the Development of CDx
5.5 Other Disease Indication Opportunities in the Companion Diagnostics Market
5.6 Companion Diagnostic/Pharma Partnerships, 2013-2014
6. Business Models and Stakeholders in the Companion Diagnostics
6.1 Business Models for the Development of Companion Diagnostics
6.1.1 The Partnership Model is the Most Practiced Method
6.1.2 The Stand-alone Model: Licensing an IP
6.1.3 The One Stop Shop Model: An Approach by Large Pharma
6.1.4 Using Contract Diagnostics Organisations (CDO): An Emerging Trend
6.2 Factors Driving Companies to Enter the Companion Diagnostics Market
6.3 Stakeholders influencing the Companion Diagnostics Market
6.3.1 Pharmaceutical Companies and Diagnostic Manufacturers
6.3.2 Regulatory Authorities
6.3.3 Testing Laboratories
6.3.4 Physicians and Patients
6.3.5 Payers
6.4 Companion Diagnostics Competitive Landscape, 2015
7. Leading Companies in the Companion Diagnostics Market
7.1 Roche: Global Diagnostics Leader
7.1.1 Ventana Medical Systems (Roche)
7.1.2 Sales and Recent Performance Analysis, 2014
7.1.3 Roche Diagnostics by Region, 2014
7.1.4 Roche: Internal Growth
7.1.5 Approval of Tarceva and Cobas EGFR Mutation Test
7.1.6 Companion Diagnostic Project Pipeline
7.1.7 Roche’s Portfolio of Marketed Companion Diagnostics, 2015
7.1.8 Ventana Companion Diagnostics: New Robust Prototype Assays
7.1.9 Recent Companion Diagnostic External Collaborations, 2014-2015
7.1.9.1 Ventana/Genmab
7.1.9.2 Ferring/ Roche: CDx Development for Infertility Treatment
7.1.9.3 MedImmune (AstraZeneca)/Ventana: Assay for NSCLC Targeted Clinical Trials
7.1.9.4 Merck/Ventana: CDx for an Undisclosed Target
7.1.9.5 AstraZeneca/Roche: CDx to Support Target Drug AZD9291
7.1.9.6 Boehringer Ingelheim/Roche
7.1.9.7 ImmunoGene/ Ventana
7.1.9.8 Foundation Medicine/Roche
7.1.9.9 Acquisitions: Bolstering their Genomic-based Diagnostic Technologies
7.2 Qiagen: Leading CDx Collaborator with Pharmaceutical Companies
7.2.1 Sales and Recent Performance Analysis, 2013-2014
7.2.1.1 Sales and Recent Performance Analysis, Q1-Q3 2014
7.2.2 Companion Diagnostics Collaboration Agreements with Pharma, 2014
7.2.2.1 Collaboration with Eli Lilly
7.2.2.2 Collaboration with AstraZeneca
7.2.2.3 Collaboration with Astellas Pharma
7.2.2.4 Collaboration with Novartis
7.2.2.5 Collaborative Agreements with Technology Companies, 2014
7.2.2.5.1 Collaboration with Protagen
7.2.3 Qiagen: CDx Portfolio and Pipeline
7.3 Abbott Molecular: An Established Competitor
7.3.1 Sales and Recent Performance Analysis, 2013-2014
7.3.1.1 Sales and Recent Performance Analysis, Q1-Q3 2014
7.3.2 Abbott Molecular: Expansive Oncology Biomarker Pipeline
7.3.3 Recent Activity
7.3.3.1 Collaboration with Merck
7.3.3.2 Collaborative Efforts with Idera
7.4 Dako (Agilent)
7.4.1 Life Sciences and Diagnostics Business
7.4.2 Agilent Life Sciences and Diagnostics, Sales and recent Performance Analysis, 2014
7.4.3 Agilent: Next Generation Sequencing Platforms
7.4.4 Recent Companion Diagnostic Collaborations
7.4.4.1 Agilent/ Merck: Several Cancer Collaborations
7.4.4.2 Agilent/Pfizer: An Ongoing Collaboration
7.5 Myriad Genetics
7.5.1 Acquisition of Myriad RBM: Increases the Company’s Market Share of Companion Diagnostics
7.5.2 Companion Diagnostic Service Offerings
7.5.3 Sales and Recent Performance Analysis, 2013-2014
7.5.3.1 BART Test: A High Revenue Generating Product
7.5.3.2 Sales and Recent Performance, Q1-Q3 2014
7.5.4 Myriad Genetics Recent Collaborations
7.5.4.1 Myriad/AstraZeneca: Premarket Approval Application
7.5.4.2 Acquisition of Crescendo Bioscience: Entry into the Autoimmune Market
7.5.4.3 Myriad/ TESARO Companion Collaboration
7.6 BioMérieux
7.6.1 Sales and Recent Performance Analysis, 2013-2014
7.6.2 Sales by Region, 2013
7.6.3 Sales and Recent Performance Analysis, Q1-Q3, 2014
7.6.4 FDA Approval for Metastatic Melanoma Companion Diagnostic Test
7.6.5 Companion Diagnostics: Recent M&A Activity & Collaboration
7.6.5.1 Collaboration Gilead Sciences
7.6.5.2 Collaboration with Ipsen
7.6.5.3 Collaboration with Merck
7.7 Siemens Diagnostics
7.7.1 Siemens Diagnostics: Sales and Recent Performance Analysis, 2013-2014
7.7.2 Siemens Healthcare Research and Development for Diagnostics
7.7.3 Recent Companion Diagnostics Partnerships
7.7.3.1 Agreement with Pfizer
7.7.3.2 Collaboration with Janssen Pharmaceutical
7.7.3.3 Partnership with ViiV Healthcare
7.7.3.4 Partnership with Tocagen
7.7.3.5 Siemens Healthcare: An Uncertain Future
7.8 Thermo Fisher Scientific
7.8.1 Sales and Recent Performance Analysis, 2013-2014
7.8.1.1 Sales Performance by Region, 2013
7.8.1.2 Thermo Fisher Scientific Financial Performance, Q1-3Q 2014
7.8.2 Recent Collaborations and Acquisitions
7.8.2.1 Acquisition of Life Technologies
7.8.2.2 Acquisition of Prionics
7.8.2.3 Thermo Fisher: Developing a ‘Universal’ Companion Diagnostics Using Next Generation Sequencing
7.8.2.4 Thermo Fisher Life Technologies Collaborates with Merck Serono
7.9 Lab 21: Fast Grower in Companion Diagnostics
7.9.1 Partnership with IntegraGen
7.9.2 Partnership with an Undisclosed Major Pharmaceutical Company
7.9.3 Lab 21: A Forerunner in Offering FDA approved Companion Diagnostics
7.9.4 New Lung Cancer Companion Diagnostic Service
8. Quantitative Analysis of the Companion Diagnostics Market, 2015-2025
8.1 SWOT Analysis of the Companion Diagnostics Market
8.2 Strengths
8.2.1 A CDx Strategy Decreases the Length of Approval Process
8.2.2 Premium Prices for Companion Diagnostics
8.2.3 A CDx Development Strategy can Generate more Effective Drugs
8.2.4 Therapeutics Tied with CDx can have Safer Profiles
8.2.5 Reducing the Cost of Healthcare
8.2.6 Increased Regulatory Scrutiny on Marketed Drugs
8.2.7 Target Therapies Will Drive the CDx Market
8.3 Weaknesses
8.3.1 Reimbursement Challenges and Undervalue
8.3.2 Lack of Clear Regulatory Guidelines
8.3.3 Capital Intensity is High
8.4 Opportunities
8.4.1 Fast-growing Emerging Markets
8.4.2 Next Generation Sequencing
8.4.3 Full Oncology Pipeline and Other Drug Categories will Benefit from CDx
8.4.4 Many New CDx/ Pharma Company Partnerships
8.5 Threats
8.5.1 Complex Business Models and Business Partnerships
8.5.2 Medical Device Excise Tax
8.6 Porter’s 5 Analysis of the Companion Diagnostics Market
8.6.1 Rivalry Among Competitors [High]
8.6.2 Power of Suppliers [High]
8.6.3 Power of Buyers [Medium]
8.6.4 Threat of New Entrants [Medium]
8.6.5 Threat of Substitutes [High]
9. Expert Opinions
9.1 Interview with Dr Philip D. Cotter, Principal and Co-Founder of ResearchDx, and Laboratory Director of Pacific Diagnostics Clinical Laboratory, a subsidiary of ResearchDx
9.1.1 Contract Diagnostics: A Growing Industry
9.1.2 Identifying Companion Diagnostic Partners During the Drug Development Phase
9.1.3 Oncology is Still the Largest Category for Companion Diagnostics
9.1.4 Timing the CDx/Drug Development Phase is Key to Success
9.1.5 Companion Diagnostics: A Faster Route to Therapy Approval
9.1.6 Next Generation Sequencing: A Necessary Technology?
9.2 Professor Herbie Newell, Professor of Cancer Therapeutics, Northern Institute for Cancer Research
9.2.1 Companion Diagnostics: Also Known as Predictive Biomarkers
9.2.2 Oncology: A Promising Pipeline of Targeted Therapies
9.2.3 Technological Platforms for Biomarker Discovery
9.2.4 Cancer Targets: Some are More Challenging than Others
9.2.5 Beyond Oncology: Biomarkers could Aid Infectives
9.2.6 The Challenges of Heterogeneous Cancers
9.2.7 Cancer Research UK Drug Discovery Programme
10. Conclusion
10.1 Overview
10.2 Theranostics: A Fast Growing Market
10.3 Leading Companion Diagnostic Companies
10.4 Pharmaceutical/Diagnostic Partnership Model
10.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics
10.6 Commercial Drivers of the Companion Diagnostics Market
10.7 Commercial Restraints of the Companion Diagnostics Market
10.8 Concluding Remarks
List of Tables
Table 1.1 The CDx Market Forecast: Revenue ($bn), AGR (%), CAGR 2014-2025
Table 1.2 The German CDx Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 2.1 Examples of Clinically Relevant Cancer Biomarkers, 2015
Table 3.1 The World IVD Market: Revenue ($bn) and Market Share (%) by Segment, 2014
Table 3.2 The World CDx Market: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
Table 3.3 The World IVD and CDx Market: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
Table 3.4 Market Share (%) of CDx in the IVD Market, 2014, 2019, 2025
Table 3.5 The World Companion Diagnostics Market: Revenue ($bn), Market Share (%) by
Submarket, 2014
Table 3.6 The World Companion Diagnostics Market by Submarket: Revenue ($bn), AGR (%), CAGR (%) by Submarket, 2014-2025
Table 3.7 Market Share (%) of Submarkets in the CDx Market, 2014, 2019, 2025
Table 4.1 The Leading National Markets for CDx: Sales ($m), Market Share (%), 2014
Table 4.2 The Leading National Companion Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.3 Market Share (%) of the National Markets in the CDx Market, 2014, 2019, 2025
Table 4.4 The US CDx Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.5 Leading US Companion Diagnostic Companies, 2015
Table 4.6 The EU5 CDx Market Forecast: Revenue ($m), Market Share (%), 2014
Table 4.7 The EU5 Companion Diagnostic National Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.8 Market Share (%) of Each EU5 Region in the CDx Market, 2014, 2019, 2025
Table 4.9 The German CDx Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.10 The French CDx Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.11 The Italian CDx Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.12 The Spanish CDx Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.13 The UK CDx Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.14 The Japanese CDx Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.15 The Chinese CDx Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.16 The Indian CDx Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.17 The Brazilian CDx Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.18 The Russian CDx Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.19 The South Korean CDx Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.20 The Mexican CDx Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.21 The Rest of the World CDx Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.1 List of FDA-approved Drugs with Pharmacogenomic Biomarker information in their
Labelling
Table 5.2 List of Cleared or Approved Companion Diagnostic Devices and their Complementary Therapeutic Drug, 2015
Table 5.3 List of CDx Diagnostic/Pharma Partnerships, 2013-2014
Table 6.1 List of Companies in the Companion Diagnostics Market, 2015
Table 7.1 Roche: Revenue ($bn), Revenue Share (%) by Sector, 2014
Table 7.2 Roche Diagnostics: Revenue ($bn), Revenue Shares (%) by Region, 2014
Table 7.3 Roche: Major Companion Diagnostic Projects, 2015
Table 7.4 Roche Diagnostics: List of Marketed Companion Diagnostics, 2015
Table 7.5 Qiagen: Revenue ($m), Revenue Share (%) by Business Sector, 2013
Table 7.6 Abbott Molecular: Biomarker Pipeline, 2015
Table 7.7 Myriad Genetics: Biomarker Product Portfolio, 2015
Table 7.8 Myriad Genetics: Revenue ($m), and Revenue Shares (%) by Sector, 2013
Table 7.9 Myriad Genetics: Revenue ($m), and Revenue Shares (%) by Product Type, 2012- 2013
Table 7.10 BioMérieux: Revenue Sales ($m), Percentage Change (%) by Region, 2012-2013
Table 7.11 Thermo Fisher Scientific: Revenue Sales ($bn), AGR (%) by Business Sector, 2012-2013
Table 7.12 Thermo Fisher Scientific: Revenue ($bn), Revenue Share (%) by Region, 2013
Table 7.13 Thermo Fisher Scientific: Revenue Sales ($bn), AGR (%) by Business Sector, Q1-Q3, 2013-2014
Table 8.1 SWOT Analysis of the Companion Diagnostics Market, 2015-2025
Table 8.2 Average Response Rate to Treatment for Various Diseases, 2015
Table 10.1 Theranostics and Other In Vitro Diagnostics: Global Sales Forecast ($bn), 2014, 2019 and 2025
List of Figures
Figure 1.1 Forecast Global Population Over the Age of 65 Years Old (millions), Annual Growth Rate (%), 2014-2025
Figure 1.2 Companion Diagnostics: Overview of Submarkets
Figure 2.1 Development of Biomarkers into Companion Diagnostics, 2015
Figure 3.1 The World IVD Market: Market Share (%) in the IVD Market, 2014
Figure 3.2 The World CDx Market: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
Figure 3.3 The World IVD and CDx Market: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
Figure 3.4 The World CDx Market Share (%) in the IVD Market, 2019
Figure 3.5 The World CDx Market Share (%) in the IVD Market, 2025
Figure 3.6 The World Companion Diagnostics Market: Market Share (%) by Submarket, 2014
Figure 3.7 The World CDx Market by Submarket: Revenue ($bn), AGR (%), AGR (%), 2014-2025
Figure 3.8 The World CDx Market Share (%) in the IVD Market, 2019
Figure 3.9 The World CDx Market Share (%) in the IVD Market, 2025
Figure 3.10 The CDx Market: Market Shares (%) by Sector in the IVD Market, 2014
Figure 4.1 The Leading National Markets for CDx by Sales ($m), 2014
Figure 4.2 The Leading National Markets for CDx by Market Share (%), 2014
Figure 4.3 The Leading National Markets for CDx by Market Share (%), 2019
Figure 4.4 The Leading National Markets for CDx by Market Share (%), 2025
Figure 4.5 The US CDx Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 4.6 The EU5 Leading National Markets for CDx by Revenue ($m), 2014
Figure 4.7 The EU5 Leading National Markets for CDx by Market Share (%), 2014
Figure 4.8 The EU5 National Markets for CDx by Market Share (%), 2019
Figure 4.9 The EU5 National Markets for CDx by Market Share (%), 2025
Figure 4.10 The German CDx Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.11 The French CDx Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.12 The Italian CDx Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.13 The Spanish CDx Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.14 The UK CDx Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.15 The Japanese CDx Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 4.16 The Chinese CDx Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.17 The Indian CDx Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.18 The Brazilian CDx Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.19 The Russian CDx Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.20 The South Korean CDx Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.21 The Mexican CDx Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.22 The Rest of the World CDx Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.1 The Market Potential of Companion Diagnostics Across Leading Disease Indications, 2015
Figure 6.1 Current Business Models for the Development of Companion Diagnostics, 2015
Figure 6.2 Stakeholders in the Companion Diagnostics Market, 2015
Figure 7.1 Roche: Revenue ($bn) by Sector, 2014
Figure 7.2 Roche: Revenue Shares (%) by Sector, 2014
Figure 7.3 Qiagen: Revenue ($m), Net Income ($m) and Profit Margin (%), 2008-2013
Figure 7.4 Qiagen: Revenue ($m), Net Income ($m) and Profit Margin (%), Q1-Q3, 2013-2014
Figure 7.5 Abbott Diagnostic: Historical Revenue ($m), 2011-2013
Figure 7.6 Abbott Laboratories: Revenue Share (%) by Business Sector, 2013
Figure 7.7 Abbott Diagnostic: Historical Revenue ($m), Q1-Q3, 2013-2014
Figure 7.8 Agilent Life Sciences and Diagnostics: Revenue ($m), Net Income ($m) and Profit Margin (%), 2011-2014
Figure 7.9 Myriad Genetics: Revenue ($m), Net Income ($m) and Profit Margin (%), 2011-2013
Figure 7.10 Myriad Genetics: Revenue Share (%) by Product Type, 2013
Figure 7.11 Myriad Genetics: Revenue ($m), Q1-Q3, 2013-2014
Figure 7.12 BioMérieux: Revenue ($m), Net Income ($m) and Profit Margin (%), 2012-2013
Figure 7.13 BioMérieux: Revenue ($m) by Region, 2013
Figure 7.14 BioMérieux: Revenue Share (%) by Region, 2013
Figure 7.15 BioMérieux: Revenue ($m), Q1-Q3, 2013-2014
Figure 7.16 Siemens Diagnostics: Revenue ($bn), Profit ($bn), Profit Margin (%), 2013-2014
Figure 7.17 Thermo Fisher Scientific: Revenue Sales ($bn) by Business Sector, 2013
Figure 7.18 Thermo Fisher Scientific: Revenue ($bn) by Region, 2013
Figure 7.19 Thermo Fisher Scientific: Revenue Share (%) by Region, 2013
Figure 7.20 Thermo Fisher Scientific: Revenue Sales ($bn) by Business Sector, Q1-Q3, 2014
Figure 8.1 Drivers and Restraints in the Companion Diagnostics Market, 2015-2025
Figure 8.2 Average Response Rates (%) for Various Diseases, 2015
Figure 8.3 Porter’s Five Analysis of the Companion Diagnostics Market, 2015-2025
Figure 10.1 The Companion Diagnostics, Global Sales Forecast ($bn), 2014-2025
Figure 10.2 Theranostics and Other In Vitro Diagnostics: World Sales Forecast ($bn), 2014, 2019, 2025
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
